https://mindmedicinelaw.com/briefing/epa-s-snur-proposal-implications-for-psychedelic-research-20260610-11563The Psychedelic Journalen2026-06-10T15:06:41.610052+00:00EPA's SNUR Proposal: Implications for Psychedelic ResearchEPA, SNURs, TSCA, psychedelic research, chemical substances, regulatory compliance, manufacturing, processing, premanufacture notices, policy implicationshttps://mindmedicinelaw.com/briefing/psychedelics-and-adhd-systematic-review-highlights-research-gaps-20260610-11608The Psychedelic Journalen2026-06-10T15:06:30.332341+00:00Psychedelics and ADHD: Systematic Review Highlights Research Gapspsychedelics, ADHD treatment, systematic review, clinical trials, neuropsychiatric disorders, LSD, psilocybin, ketamine, serotonin receptors, psychedelic researchhttps://mindmedicinelaw.com/briefing/optimi-health-exports-psilocybin-for-uk-phase-2-trial-20260610-11686The Psychedelic Journalen2026-06-10T15:05:41.130938+00:00Optimi Health Exports Psilocybin for UK Phase 2 Trialpsilocybin export, Optimi Health, UK clinical trial, international collaboration, psychedelic research, regulatory framework, mental health treatment, Phase 2 trial, controlled substances, global healthcarehttps://mindmedicinelaw.com/briefing/psychedelic-trials-methodology-faces-critical-review-20260609-11436The Psychedelic Journalen2026-06-09T15:03:58.478710+00:00Psychedelic Trials' Methodology Faces Critical Reviewpsychedelic trials, methodology scrutiny, clinical research, placebo controls, trial design, regulatory standards, psilocybin, MDMA, FDA approval, scientific integrityhttps://mindmedicinelaw.com/briefing/chicago-va-s-psilocybin-therapy-for-veterans-with-ptsd-20260609-11437The Psychedelic Journalen2026-06-09T15:03:46.616586+00:00Chicago VA's Psilocybin Therapy for Veterans with PTSDpsilocybin therapy, PTSD treatment, veterans mental health, psychedelic research, Chicago VA Hospital, psychiatric protocols, mental health care, clinical trials, psychedelic therapies, psychiatric treatmenthttps://mindmedicinelaw.com/briefing/n-acetylcysteine-in-ocd-treatment-promising-trial-results-20260608-11621The Psychedelic Journalen2026-06-10T15:06:05.307550+00:00N-acetylcysteine in OCD Treatment: Promising Trial Resultsn-acetylcysteine, obsessive-compulsive disorder, sertraline, clinical trial, adjunctive treatment, SSRI, glutamate modulation, Y-BOCS, placebo-controlled, cognitive functioninghttps://mindmedicinelaw.com/briefing/ketamine-vs-esketamine-depression-treatment-in-germany-20260608-11622The Psychedelic Journalen2026-06-10T15:05:53.086498+00:00Ketamine vs. Esketamine: Depression Treatment in Germanyketamine infusions, esketamine nasal spray, treatment-resistant depression, cost-effectiveness, German healthcare, clinical guidelines, psychedelic research, mental health policy, NMDA receptor, off-label usehttps://mindmedicinelaw.com/briefing/neuroinflammation-s-impact-on-treatment-resistant-depression-20260608-11510The Psychedelic Journalen2026-06-09T22:03:15.367776+00:00Neuroinflammation's Impact on Treatment-Resistant Depressiontreatment-resistant depression, neuroinflammation, personalized medicine, inflammatory markers, next-generation antidepressants, blood-brain barrier, major depressive disorder, immune system, mental health, biological subtypeshttps://mindmedicinelaw.com/briefing/meta-analysis-psychedelics-for-ptsd-treatment-20260608-11509The Psychedelic Journalen2026-06-09T22:02:58.037978+00:00Meta-Analysis: Psychedelics for PTSD TreatmentMDMA, PTSD, psychedelic-assisted psychotherapy, ketamine, cannabidiol, systematic review, meta-analysis, randomized controlled trials, efficacy, safetyhttps://mindmedicinelaw.com/briefing/fda-s-comp360-approval-path-implications-for-psychedelics-20260608-11286The Psychedelic Journalen2026-06-08T22:04:13.815212+00:00FDA's COMP360 Approval Path: Implications for PsychedelicsFDA approval, COMP360, REMS, psilocybin therapy, psychedelic industry, regulatory process, investor implications, clinical trials, risk management, psychedelic researchhttps://mindmedicinelaw.com/briefing/mdma-assisted-therapy-in-social-anxiety-disorder-trials-20260604-11496The Psychedelic Journalen2026-06-09T22:03:07.065122+00:00MDMA-Assisted Therapy in Social Anxiety Disorder Trialsmdma-assisted therapy, social anxiety disorder, clinical trials, psychedelics, mental health, treatment efficacy, neuroscience, public health, regulatory considerations, adverse eventshttps://mindmedicinelaw.com/briefing/ketamine-s-mechanisms-expand-beyond-nmda-antagonism-20260601-11684The Psychedelic Journalen2026-06-10T15:06:15.200768+00:00Ketamine's Mechanisms Expand Beyond NMDA Antagonismketamine, NMDA receptor, mental health treatment, neuroscience, clinical trials, psychedelic research, therapeutic potential, glutamate transmission, neurotransmitter systems